PMID- 27711130 OWN - NLM STAT- MEDLINE DCOM- 20170620 LR - 20220408 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 11 IP - 10 DP - 2016 TI - Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. PG - e0161811 LID - 10.1371/journal.pone.0161811 [doi] LID - e0161811 AB - BACKGROUND: The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. METHOD: The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL. RESULTS: Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia. CONCLUSION: The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL. FAU - Yang, Ya-Ting AU - Yang YT AD - Institute of Health Policy and Management, National Taiwan University, 17 Xu-Zhou Rd., Taipei, 100, Taiwan. AD - Golden Dream Think Tank and Research Center, 17 Songjiang Rd., Taipei, 104, Taiwan. AD - School of Health Care Administration, Taipei Medical University, 250 Wuxing Street, Taipei, Taiwan. FAU - Tai, Cheng-Jeng AU - Tai CJ AD - Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, 252 Wuxing Street, Taipei, 110, Taiwan. AD - Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 110, Taiwan. FAU - Chen, Chiehfeng AU - Chen C AD - Center for Evidence-Based Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 110, Taiwan. AD - Department of Public Health, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 110, Taiwan. AD - Division of Plastic Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, NO.111, Section 3, Hsing-Long Rd, Taipei, 116, Taiwan. AD - Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, NO.111, Section 3, Hsing-Long Rd, Taipei, 116, Taiwan. FAU - Wu, Hong-Cheng AU - Wu HC AD - Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, 252 Wuxing Street, Taipei, 110, Taiwan. FAU - Mikhaylichenko, Natalia AU - Mikhaylichenko N AD - Nevron, International Medical Center, Vladivostok, Russia. FAU - Chiu, Hsien-Tsai AU - Chiu HT AD - Golden Dream Think Tank and Research Center, 17 Songjiang Rd., Taipei, 104, Taiwan. AD - Department of Public Health, China Medical University, 91 Hsueh-Shih Road, Taichung, 404, Taiwan. FAU - Chen, Yun-Yi AU - Chen YY AD - Institute of Health Policy and Management, National Taiwan University, 17 Xu-Zhou Rd., Taipei, 100, Taiwan. AD - Golden Dream Think Tank and Research Center, 17 Songjiang Rd., Taipei, 104, Taiwan. FAU - Hsu, Yi-Hsin Elsa AU - Hsu YE AD - Golden Dream Think Tank and Research Center, 17 Songjiang Rd., Taipei, 104, Taiwan. AD - School of Health Care Administration, Taipei Medical University, 250 Wuxing Street, Taipei, Taiwan. LA - eng PT - Journal Article PT - Review PT - Systematic Review DEP - 20161006 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Disease-Free Survival MH - Humans MH - Lymphoma, T-Cell, Peripheral/*therapy MH - Recurrence MH - Salvage Therapy/*methods MH - Treatment Outcome PMC - PMC5053427 COIS- The authors have declared that no competing interests exist. We have noted that the financial support does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2016/10/07 06:00 MHDA- 2017/06/21 06:00 PMCR- 2016/10/06 CRDT- 2016/10/07 06:00 PHST- 2015/09/04 00:00 [received] PHST- 2016/08/12 00:00 [accepted] PHST- 2016/10/07 06:00 [entrez] PHST- 2016/10/07 06:00 [pubmed] PHST- 2017/06/21 06:00 [medline] PHST- 2016/10/06 00:00 [pmc-release] AID - PONE-D-15-37580 [pii] AID - 10.1371/journal.pone.0161811 [doi] PST - epublish SO - PLoS One. 2016 Oct 6;11(10):e0161811. doi: 10.1371/journal.pone.0161811. eCollection 2016.